PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Clear-cell sarcoma

Drugs in development · updated 30 October 2026

Clear-cell sarcoma: drugs in development

As of 30 October 2026 there are 8 active clinical trials (recruiting or ongoing, phases I–III) on 14 drugs for clear-cell sarcoma. One is experimental, that is not yet approved in the United States.

8Active trials
1Experimental drugs
0Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
VebreltinibPLB1001, APL-101II1NCT07153887

Sorted by most advanced phase and number of active trials.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
AtezolizumabTecentriq, MPDL3280AII1NCT04458922
CabozantinibResniben®, Cabometyx®II1NCT02867592
Cabozantinib S-malateCabometyx®, Cometriq®II1NCT02867592
DoxorubicinAdriamycin, DoxorubincinI–II1NCT06239272
IfosfamideI–II1NCT06239272
PazopanibVotrient®I–II1NCT06239272
SelinexorKPT-330, Xpovio®I–II1NCT06239272
TebentafuspKimmtrak®II1NCT06942442
Zoledronic AcidZoledronate, Zoledronic acideI–II1NCT06625190
CyclophosphamideCyclophosphamid, CytoxanI1NCT04897321
FludarabineFludara, FLUDARABINI1NCT04897321
MesnaUromitexan, Mesnex®I1NCT04897321
PembrolizumabKEYTRUDA, MK-3475I1NCT04483778

Sorted by most advanced phase and number of active trials.

All 14 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D018227 “Sarcoma, Clear Cell”.

ItalianoFrançaisDeutsch